Good thoughts, we could also have a peer reviewed journal article on K by that time, Prurisol Phase 2 results (and P3 plans if not commencement, given success in current trial, which should also beget a BP partnership, which would add another 5x stock price), K Ovarian P 2/3 trial approval and imminent start, B ulcerative proctitis and colitis trial plans dialogues with FDA, B prophylactic trials being planned for medical devices and such, research analyst coverage by the major selling side broker/dealers, substantail institutional ownership, and more :)
News 
Market Data 
Discover 
